Showing 1941-1950 of 3134 results for "".
- Sciton Gives Back for Breast Cancer Awareness Monthhttps://modernaesthetics.com/news/sciton-gives-back-for-breast-cancer-awareness-month/2472194/Sciton, Inc.’s Women's Health Group division and the Young Survival Coalition (YSC) are partnering to raise awareness about women's vaginal health, in particular, those who are recovering from breast can
- USA, Brazil Take the Lead for Most Plastic Surgery Procedureshttps://modernaesthetics.com/news/usa-brazil-take-the-lead-for-most-plastic-surgery-procedures/2472215/Plastic surgery is on the rise across the globe, according to new statistics from The International Society of Aesthetic Plastic Surgery (ISAPS). There was an overall increase of 9 percent in surgical and non-surgical cosmetic procedures in 2016.
- ASAPS 2016: Labiaplasty More Than A Fadhttps://modernaesthetics.com/news/asaps-2016-labiaplasty-more-than-a-fad/2472263/When it rains, it pours. Both the American Society of Plastic Surgeons (ASPS) and sister organization American Society for Aesthetic Plastic Surgery (ASAPS) released some (ASAPS) or all (ASPS) of their annual statistics. And by and
- Imaging Study Explores Tissue Repair Dynamics After UltraClear Laser Therapyhttps://modernaesthetics.com/news/imaging-study-explores-tissue-repair-dynamics-after-ultraclear-laser-therapy/2487167/Serial line-field confocal optical coherence tomography (LC-OCT) imaging may provide a noninvasive method for visualizing tissue repair following laser-coring procedures, according to findings published in Lasers in Surgery and Medicine.1 In the technical demonstration
- SCALE 2026: Practical Strategies for Treating GLP-1 RA–Related Aesthetic Changeshttps://modernaesthetics.com/news/scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487146/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1 receptor agonists (RA)–mediated weight reduction. During a presentation at the 2026 Music City SCALE meeting
- SCALE 2026: Ipsen Reports Phase 2 Corabotase Data in Glabellar Lineshttps://modernaesthetics.com/news/scale-2026-ipsen-reports-phase-2-corabotase-data-in-glabellar-lines/2487141/Ipsen presented late-breaking Phase 2 data for corabotase, its investigational recombinant neuroinhibitor, in moderate-to-severe glabellar lines at the 2026 SCALE Symposium in Nashville, Tennessee. The study included 183 patients. At week 4, 66% of patients treated with corabotase 50 ng ac
- SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Carehttps://modernaesthetics.com/news/scale-2026-dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487119/Dermatologists Navigate the Expanding Role of GLP-1 RAs in Skin Health and Aesthetic Care As use of GLP-1 receptor agonists (RAs) continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic pract
- SCALE 2026: Ipsen to Present Phase II Corabotase Datahttps://modernaesthetics.com/news/scale-2026-ipsen-to-present-phase-ii-corabotase-data/2487087/Ipsen announced that Phase II data from the LANTIC trial of corabotase will be presented at the SCALE 2026 Symposium on May 16, 2026, in the first aesthetic glabellar lines indication for the investigational molecule. Corabotase is described by Ipsen as a custom-designed recombinant neuroi
- ASLMS 2026: Lumenis Reports New Laser Findings in Scalp Treatment, Rhinophyma, Photodamaged Skinhttps://modernaesthetics.com/news/aslms-2026-lumenis-reports-new-laser-findings-in-scalp-treatment-rhinophyma-photodamaged-skin/2487036/Lumenis Be Ltd. presented new clinical data on several aesthetic devices at the 45th Annual American Society for Laser Medicine and Surgery Conference, held May 7-9, 2026, in Savannah, Georgia, according to a company announcement. The presentations included data on FoLix, a 1565-nm nonabla
- Rapalogix Health Launches Re-Q Pro-Longevity Serum with Focus on Cellular Skin Aginghttps://modernaesthetics.com/news/rapalogix-health-launches-re-q-pro-longevity-serum-with-focus-on-cellular-skin-aging/2487003/Rapalogix Health has introduced its new Re-Q Pro-Longevity Face Serum during a virtual launch event on Thursday, May 7, featuring co-Founder and board-certified dermatologist Doris Day, MD, and co-Founder and CEO Rahul Mehta. The webinar focused on the science behind the product and the company’s